 |
 |

Effect of Hospital Type and Volume on Lymph Node Evaluation for Gastric and Pancreatic Cancer
Karl Y. Bilimoria, MD, MS;
Mark S. Talamonti, MD;
Jeffrey D. Wayne, MD;
James S. Tomlinson, MD;
Andrew K. Stewart, MA;
David P. Winchester, MD;
Clifford Y. Ko, MD, MS, MSHS;
David J. Bentrem, MD
Arch Surg. 2008;143(7):671-678.
Hypothesis For gastric and pancreatic cancer, regional lymph node evaluation is important to accurately stage disease in a patient and may be associated with improved survival. We hypothesized that National Comprehensive Cancer Network (NCCN), National Cancer Institute (NCI)–designated institutions, and high-volume hospitals examine more lymph nodes for gastric and pancreatic malignant neoplasms than do low-volume centers and community hospitals.
Design Volume-outcome study.
Setting Academic research.
Patients Using the National Cancer Data Base (January 1, 2003, to December 31, 2004), patients were identified who underwent resection for gastric (n = 3088) and pancreatic (n = 1130 [pancreaticoduodenectomy only]) cancer.
Main Outcome Measures Multivariable logistic regression analysis was used to assess the effect of hospital type and volume on nodal evaluation ( 15 nodes).
Results Only 23.2% of patients with gastric cancer and 16.4% of patients with pancreatic cancer in the United States underwent evaluation of at least 15 lymph nodes. Patients undergoing surgery had more lymph nodes examined at NCCN-NCI hospitals than at community hospitals (median, 12 vs 6 for gastric cancer and 9 vs 6 for pancreatic cancer; P < .001). Patients at highest-volume hospitals had more lymph nodes examined than patients at low-volume hospitals (median, 10 vs 6 for gastric cancer and 8 vs 6 for pancreatic cancer; P < .001). On multivariable analysis, patients undergoing surgery at NCCN-NCI and high-volume hospitals were more likely to have at least 15 lymph nodes evaluated compared with patients undergoing surgery at community hospitals and low-volume centers (P < .001 and P =.02, respectively).
Conclusions Nodal examination is important for staging, adjuvant therapy decision making, and clinical trial stratification. Moreover, differences in nodal evaluation may contribute to improved long-term outcomes at NCCN-NCI centers and high-volume hospitals for patients with gastric and pancreatic cancer.
Author Affiliations: Cancer Programs, American College of Surgeons (Drs Bilimoria, Winchester, and Ko and Mr Stewart) Chicago, Illinois; and Departments of Surgery, Feinberg School of Medicine, Northwestern University (Drs Bilimoria, Wayne, and Bentrem), and Evanston Northwestern Healthcare (Drs Talamonti and Winchester), Chicago, Illinois, and University of California, Los Angeles; and Veterans Affairs Greater Los Angeles Healthcare System (Drs Tomlinson and Ko).
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Assessment of Pancreatic Cancer Care in the United States Based on Formally Developed Quality Indicators
Bilimoria et al.
JNCI J Natl Cancer Inst 2009;101:848-859.
ABSTRACT
| FULL TEXT
|